Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

November 16, 2020November 16, 2020

$380K Fox Foundation Grant Extends California Parkinson’s Registry for Year

News

The California Parkinson’s Disease Registry (CPDR) will continue through June 2021, after gaining support from the state’s governor and $380,000 in extension funding from the Michael J. Fox Foundation for ... Read more

October 29, 2020October 29, 2020

NIH Grant Supports Syn-One Test for Detecting Parkinson’s, Other Disorders Early

News

The U.S. National Institutes of Health (NIH) has given a Small Business Innovation Research (SBIR) grant totaling $2.4 million to Cutaneous NeuroDiagnostics (CND) to advance development of its Syn-One Test ... Read more

October 19, 2020October 20, 2020

Pharmather to Advance Ketamine as Potential Dyskinesia Treatment

News

Pharmather has entered into an exclusive licensing agreement with the University of Arizona, allowing the company to further develop ketamine as a potential treatment of dyskinesia — involuntary, jerky movements — associated ... Read more

October 9, 2020October 9, 2020

STADA Acquires Triple Combo Pump Therapy, Seeks European Approvals

News

STADA Arzneimittel has announced the acquisition of Sweden-based Lobsor Pharmaceuticals, gaining the rights to its triple-combination therapy of levodopa, carbidopa, and entacapone, delivered via modern pump technology, as a treatment ... Read more

October 6, 2020October 6, 2020

BIAL Acquires Parkinson’s Treatment LTI-291, Opens US Research Center

News

Portuguese pharmaceutical company BIAL has announced the opening of a Parkinson’s disease research facility in Cambridge, Mass., as part of its expansion to the United States under the name BIAL ... Read more

September 30, 2020September 30, 2020

$7M Grant Awarded to Develop NISNEM (Non-Invasive, Individual Brain Cell Imaging Technology)

News

The Engineering and Physical Research Sciences Council (EPRSC) at UK Research and Innovation (UKRI) has awarded researchers at Imperial College London with a £5.5 million ($7.07 million) grant to develop ... Read more

September 28, 2020September 28, 2020

iLCT Program Pledges $6.75M for Clinical Trials for Potential Treatments

News

The International Linked Clinical Trials (iLCT) program, a collaborative effort from The Cure Parkinson’s Trust (CPT), the Van Andel Institute (VAI), and now the John Black Charitable Foundation (JBCF), has ... Read more

September 18, 2020September 18, 2020

Trial Testing CuraSen’s CST-2032 for Neurodegenerative Disease Begins Dosing

News

The first participants have been dosed in the initial part of a Phase 1 clinical trial evaluating the investigational compound CST-2032 as a treatment for neurodegenerative disease, according to the ... Read more

September 4, 2020September 4, 2020

American Parkinson Disease Association Awards First Diversity Research Grant

News

The American Parkinson Disease Association (APDA) has awarded $1.4 million toward research into Parkinson’s disease for 2020–2021, including the first-ever Diversity in Parkinson’s Disease Research Grant. Following the first APDA ... Read more

September 3, 2020September 3, 2020

First Patients Dosed in Clinical Trial Investigating ANVS401 as Treatment for Parkinson’s and Alzheimer’s

News

The first three patients have been dosed in a Phase 2a clinical trial investigating the safety and effectiveness of ANVS401, Annovis Bio’s lead compound designed as a potential treatment for Parkinson’s ... Read more